Cargando…

Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling

A double ampC (AmpC(G183D)) and ampD (AmpD(H157Y)) genes mutations have been identified by whole genome sequencing in a Pseudomonas aeruginosa (PaS) that became resistant (PaR) in a patient treated by ceftolozane/tazobactam (C/T). To precisely characterize the respective contributions of these mutat...

Descripción completa

Detalles Bibliográficos
Autores principales: Deroche, Luc, Aranzana-Climent, Vincent, Rozenholc, Albane, Prouvensier, Laure, Darnaud, Léa, Grégoire, Nicolas, Marchand, Sandrine, Ploy, Marie-Cécile, François, Bruno, Couet, William, Barraud, Olivier, Buyck, Julien M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583683/
https://www.ncbi.nlm.nih.gov/pubmed/37695298
http://dx.doi.org/10.1128/aac.00480-23
_version_ 1785122605254049792
author Deroche, Luc
Aranzana-Climent, Vincent
Rozenholc, Albane
Prouvensier, Laure
Darnaud, Léa
Grégoire, Nicolas
Marchand, Sandrine
Ploy, Marie-Cécile
François, Bruno
Couet, William
Barraud, Olivier
Buyck, Julien M.
author_facet Deroche, Luc
Aranzana-Climent, Vincent
Rozenholc, Albane
Prouvensier, Laure
Darnaud, Léa
Grégoire, Nicolas
Marchand, Sandrine
Ploy, Marie-Cécile
François, Bruno
Couet, William
Barraud, Olivier
Buyck, Julien M.
author_sort Deroche, Luc
collection PubMed
description A double ampC (AmpC(G183D)) and ampD (AmpD(H157Y)) genes mutations have been identified by whole genome sequencing in a Pseudomonas aeruginosa (PaS) that became resistant (PaR) in a patient treated by ceftolozane/tazobactam (C/T). To precisely characterize the respective contributions of these mutations on the decreased susceptibility to C/T and on the parallel increased susceptibility to imipenem (IMI), mutants were generated by homologous recombination in PAO1 reference strain (PAO1- AmpC(G183D), PAO1-AmpD(H157Y), PAO1-AmpC(G183D)/AmpD(H157Y)) and in PaR (PaR-AmpC(PaS)/AmpD(PaS)). Sequential time-kill curve experiments were conducted on all strains and analyzed by semi-mechanistic PKPD modeling. A PKPD model with adaptation successfully described the data, allowing discrimination between initial and time-related (adaptive resistance) effects of mutations. With PAO1 and mutant-derived strains, initial EC(50) values increased by 1.4, 4.1, and 29-fold after AmpC(G183D) , AmpD(H157Y) and AmpC(G183D)/AmpD(H157Y) mutations, respectively. EC(50) values were increased by 320, 12.4, and 55-fold at the end of the 2 nd experiment. EC(50) of PAO1-AmpC(G183D)/AmpD(H157Y) was higher than that of single mutants at any time of the experiments. Within the PaR clinical background, reversal of AmpC(G183D), and AmpD(H157Y) mutations led to an important decrease of EC(50) value, from 80.5 mg/L to 6.77 mg/L for PaR and PaR-AmpC(PaS)/AmpD(PaS), respectively. The effect of mutations on IMI susceptibility mainly showed that the AmpC(G183D) mutation prevented the emergence of adaptive resistance. The model successfully described the separate and combined effect of AmpC(G183D) and AmpD(H157Y) mutations against C/T and IMI, allowing discrimination and quantification of the initial and time-related effects of mutations. This method could be reproduced in clinical strains to decipher complex resistance mechanisms.
format Online
Article
Text
id pubmed-10583683
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-105836832023-10-19 Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling Deroche, Luc Aranzana-Climent, Vincent Rozenholc, Albane Prouvensier, Laure Darnaud, Léa Grégoire, Nicolas Marchand, Sandrine Ploy, Marie-Cécile François, Bruno Couet, William Barraud, Olivier Buyck, Julien M. Antimicrob Agents Chemother Mechanisms of Resistance A double ampC (AmpC(G183D)) and ampD (AmpD(H157Y)) genes mutations have been identified by whole genome sequencing in a Pseudomonas aeruginosa (PaS) that became resistant (PaR) in a patient treated by ceftolozane/tazobactam (C/T). To precisely characterize the respective contributions of these mutations on the decreased susceptibility to C/T and on the parallel increased susceptibility to imipenem (IMI), mutants were generated by homologous recombination in PAO1 reference strain (PAO1- AmpC(G183D), PAO1-AmpD(H157Y), PAO1-AmpC(G183D)/AmpD(H157Y)) and in PaR (PaR-AmpC(PaS)/AmpD(PaS)). Sequential time-kill curve experiments were conducted on all strains and analyzed by semi-mechanistic PKPD modeling. A PKPD model with adaptation successfully described the data, allowing discrimination between initial and time-related (adaptive resistance) effects of mutations. With PAO1 and mutant-derived strains, initial EC(50) values increased by 1.4, 4.1, and 29-fold after AmpC(G183D) , AmpD(H157Y) and AmpC(G183D)/AmpD(H157Y) mutations, respectively. EC(50) values were increased by 320, 12.4, and 55-fold at the end of the 2 nd experiment. EC(50) of PAO1-AmpC(G183D)/AmpD(H157Y) was higher than that of single mutants at any time of the experiments. Within the PaR clinical background, reversal of AmpC(G183D), and AmpD(H157Y) mutations led to an important decrease of EC(50) value, from 80.5 mg/L to 6.77 mg/L for PaR and PaR-AmpC(PaS)/AmpD(PaS), respectively. The effect of mutations on IMI susceptibility mainly showed that the AmpC(G183D) mutation prevented the emergence of adaptive resistance. The model successfully described the separate and combined effect of AmpC(G183D) and AmpD(H157Y) mutations against C/T and IMI, allowing discrimination and quantification of the initial and time-related effects of mutations. This method could be reproduced in clinical strains to decipher complex resistance mechanisms. American Society for Microbiology 2023-09-11 /pmc/articles/PMC10583683/ /pubmed/37695298 http://dx.doi.org/10.1128/aac.00480-23 Text en Copyright © 2023 Deroche et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Mechanisms of Resistance
Deroche, Luc
Aranzana-Climent, Vincent
Rozenholc, Albane
Prouvensier, Laure
Darnaud, Léa
Grégoire, Nicolas
Marchand, Sandrine
Ploy, Marie-Cécile
François, Bruno
Couet, William
Barraud, Olivier
Buyck, Julien M.
Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling
title Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling
title_full Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling
title_fullStr Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling
title_full_unstemmed Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling
title_short Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling
title_sort characterization of pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampc and/or ampd mutations observed during treatment using semi-mechanistic pkpd modeling
topic Mechanisms of Resistance
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583683/
https://www.ncbi.nlm.nih.gov/pubmed/37695298
http://dx.doi.org/10.1128/aac.00480-23
work_keys_str_mv AT derocheluc characterizationofpseudomonasaeruginosaresistancetoceftolozanetazobactamduetoampcandorampdmutationsobservedduringtreatmentusingsemimechanisticpkpdmodeling
AT aranzanaclimentvincent characterizationofpseudomonasaeruginosaresistancetoceftolozanetazobactamduetoampcandorampdmutationsobservedduringtreatmentusingsemimechanisticpkpdmodeling
AT rozenholcalbane characterizationofpseudomonasaeruginosaresistancetoceftolozanetazobactamduetoampcandorampdmutationsobservedduringtreatmentusingsemimechanisticpkpdmodeling
AT prouvensierlaure characterizationofpseudomonasaeruginosaresistancetoceftolozanetazobactamduetoampcandorampdmutationsobservedduringtreatmentusingsemimechanisticpkpdmodeling
AT darnaudlea characterizationofpseudomonasaeruginosaresistancetoceftolozanetazobactamduetoampcandorampdmutationsobservedduringtreatmentusingsemimechanisticpkpdmodeling
AT gregoirenicolas characterizationofpseudomonasaeruginosaresistancetoceftolozanetazobactamduetoampcandorampdmutationsobservedduringtreatmentusingsemimechanisticpkpdmodeling
AT marchandsandrine characterizationofpseudomonasaeruginosaresistancetoceftolozanetazobactamduetoampcandorampdmutationsobservedduringtreatmentusingsemimechanisticpkpdmodeling
AT ploymariececile characterizationofpseudomonasaeruginosaresistancetoceftolozanetazobactamduetoampcandorampdmutationsobservedduringtreatmentusingsemimechanisticpkpdmodeling
AT francoisbruno characterizationofpseudomonasaeruginosaresistancetoceftolozanetazobactamduetoampcandorampdmutationsobservedduringtreatmentusingsemimechanisticpkpdmodeling
AT couetwilliam characterizationofpseudomonasaeruginosaresistancetoceftolozanetazobactamduetoampcandorampdmutationsobservedduringtreatmentusingsemimechanisticpkpdmodeling
AT barraudolivier characterizationofpseudomonasaeruginosaresistancetoceftolozanetazobactamduetoampcandorampdmutationsobservedduringtreatmentusingsemimechanisticpkpdmodeling
AT buyckjulienm characterizationofpseudomonasaeruginosaresistancetoceftolozanetazobactamduetoampcandorampdmutationsobservedduringtreatmentusingsemimechanisticpkpdmodeling